Acorda target cut to $19 to account for Ampyra generics, Inbrija delay at Stifel

Stifel analyst Paul Matteis lowered his price target on Acorda Therapeutics shares to account for the arrival of Ampyra generics and the FDA’s extension of Inbrija’s PDUFA to early next year, which leads him to move his Inbrija launch expectation back by a quarter to the first quarter of 2019. The analyst, who cut his target to $19 from $25, keeps a Hold rating on Acorda shares.
https://thefly.com/landingPageNews.php?id=2800293